How to Develop a National Formulary Based on the WHO Model Formulary - A Practical Guide
(2004; 45 pages) View the PDF document
Table of Contents
View the documentAbbreviations
Open this folder and view contents1 INTRODUCTION
Close this folder2 OVERVIEW OF THE NATIONAL FORMULARY PROCESS
Close this folderOrganization of the national formulary committee
View the documentThe editorial team
View the documentThe advisory group
View the documentAgreement on purpose, content, structure and format
View the documentFinancing
View the documentSelection of medicines to be included in the national formulary
View the documentDevelopment of the draft
View the documentReviewing and finalizing content
View the documentProduction, dissemination and implementation
View the documentEvaluation and review
Open this folder and view contents3 DEVELOPING THE PRELIMINARY INFORMATION SECTION
Open this folder and view contents4 DEVELOPMENT OF THERAPEUTIC INFORMATION AND MONOGRAPHS USING THE WHO MODEL FORMULARY
Open this folder and view contents5 ADDITIONAL SOURCES OF INFORMATION
Open this folder and view contents6 DEVELOPING SPECIFIC INFORMATION SECTIONS
Open this folder and view contents7 PRODUCTION, DISTRIBUTION AND IMPLEMENTATION
Open this folder and view contents8 EVALUATION
Open this folder and view contents9 REVIEW AND UPDATE
View the documentREFERENCES
 

Organization of the national formulary committee

The national formulary committee (NFC) makes final decisions on the purpose, structure, content and format of the NF. This group should be limited in size to enable effective functioning and should act with the endorsement of national policy-making bodies. If there is an established essential drug programme (EDP) in the country, then the existing multidisciplinary committee or a subcommittee of it can serve as the NFC.

If there is no EDP committee or any other national medicine or therapeutic committee then a NFC should be formed. This committee should include practising physicians, clinical pharmacists, pharmacologists and medical specialists. Asking professional bodies (national medical and pharmaceutical associations) to nominate representatives can lead to better acceptance of NF through widespread ownership. Care should also be taken to ensure that the group is balanced geographically, with representatives from all areas of the country.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: August 29, 2014